A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients

AstraZeneca

Status and phase: Completed; Phase 2

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Treatments: Drug: Placebo; Drug: AZD9668

Study type: Interventional

Funder types: Industry

Identifiers

NCT00703391

D0520C00002

Details and patient eligibility

About

The purpose of this study is to assess the tolerability (effect of drug on body) and pharmacokinetics (effect of body on drug) of AZD9668 in patients with mild to moderate COPD

Enrollment: 18 patients

Sex: All

Ages: 40 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Mild to moderate COPD
• Smokers or ex-smokers
• post-menopausal females

Exclusion criteria

• Past history or current evidence of clinically significant heart disease
• Lung disease other than COPD
• Treatment with systemic steroids within 8 weeks of study visit 2
• Treatment with antibiotics within 4 weeks of study visit 1 or study visit 2

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

18 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

Active Treatment

Treatment:

Drug: AZD9668

2

Placebo Comparator group

Description:

Placebo Treatment

Treatment:

Drug: Placebo